Balance Sheet: Liabilities and Stockholders’ Equity
Quarterly Data

The balance sheet provides creditors, investors, and analysts with information on company resources (assets) and its sources of capital (its equity and liabilities). It normally also provides information about the future earnings capacity of a company assets as well as an indication of cash flows that may come from receivables and inventories.

Liabilities represents obligations of a company arising from past events, the settlement of which is expected to result in an outflow of economic benefits from the entity.

Biogen Inc., consolidated balance sheet: liabilities and stockholders’ equity (quarterly data)

US$ in thousands

	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019	Dec 31, 2018	Sep 30, 2018	Jun 30, 2018	Mar 31, 2018	Dec 31, 2017	Sep 30, 2017	Jun 30, 2017	Mar 31, 2017
Current portion of notes payable	—)	999,800)	999,500)	999,100)	998,800)	—)	—)	—)	—)	—)	1,501,800)	1,495,800)	1,495,300)	—)	—)	—)	—)	—)	3,300)	3,200)	573,200)	559,900)	561,500)
Taxes payable	237,300)	284,900)	317,300)	174,700)	234,200)	230,900)	143,100)	142,000)	119,400)	576,700)	310,000)	71,400)	125,600)	427,200)	238,500)	63,500)	254,100)	223,000)	231,900)	68,200)	121,300)	52,600)	70,000)
Accounts payable	383,200)	434,800)	398,700)	589,200)	427,900)	375,300)	430,400)	454,900)	398,400)	383,900)	389,000)	530,800)	382,200)	377,100)	378,000)	370,500)	342,300)	295,700)	345,800)	395,500)	298,700)	330,300)	316,400)
Liabilities held for sale	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	88,600)	97,200)	—)	—)	—)	—)	—)	—)	—)	—)
Accrued expense and other	3,305,900)	3,298,500)	2,231,100)	2,535,200)	2,550,700)	2,741,000)	2,592,300)	3,145,300)	3,286,200)	2,486,500)	2,437,800)	2,765,800)	2,429,100)	2,318,000)	2,435,000)	2,861,200)	2,578,500)	2,633,700)	2,571,100)	2,901,300)	2,455,200)	2,436,900)	2,044,600)
Current liabilities	3,926,400)	5,018,000)	3,946,600)	4,298,200)	4,211,600)	3,347,200)	3,165,800)	3,742,200)	3,804,000)	3,447,100)	4,638,600)	4,863,800)	4,432,200)	3,210,900)	3,148,700)	3,295,200)	3,174,900)	3,152,400)	3,152,100)	3,368,200)	3,448,400)	3,379,700)	2,992,500)
Notes payable, excluding current portion	6,279,200)	6,277,400)	6,275,700)	6,274,000)	6,272,300)	7,269,200)	7,267,200)	7,426,200)	7,425,000)	7,423,800)	4,459,900)	4,459,000)	4,458,200)	5,948,500)	5,943,200)	5,936,500)	5,931,100)	5,928,400)	5,929,400)	5,935,000)	5,938,300)	5,954,000)	5,952,700)
Deferred tax liability	328,900)	480,600)	571,200)	694,500)	774,700)	918,900)	966,700)	1,032,800)	1,123,400)	1,461,500)	2,722,800)	2,810,800)	2,820,400)	2,400,600)	1,741,700)	1,636,200)	1,114,600)	1,160,800)	1,331,100)	122,600)	120,700)	100,800)	94,500)
Long-term operating lease liabilities	354,800)	274,200)	312,300)	330,400)	348,200)	363,900)	380,000)	402,000)	409,100)	414,800)	403,700)	412,700)	410,500)	423,000)	436,100)	—)	—)	—)	—)	—)	—)	—)	—)
Other long-term liabilities	1,198,100)	1,167,800)	1,287,900)	1,320,500)	1,318,200)	1,356,400)	1,411,800)	1,329,600)	1,428,100)	1,475,400)	1,357,300)	1,348,900)	1,370,900)	1,355,800)	1,353,800)	1,389,400)	1,511,800)	1,457,600)	1,640,000)	1,628,700)	716,900)	750,900)	688,800)
Long-term liabilities	8,161,000)	8,200,000)	8,447,100)	8,619,400)	8,713,400)	9,908,400)	10,025,700)	10,190,600)	10,385,600)	10,775,500)	8,943,700)	9,031,400)	9,060,000)	10,127,900)	9,474,800)	8,962,100)	8,557,500)	8,546,800)	8,900,500)	7,686,300)	6,775,900)	6,805,700)	6,736,000)
Total liabilities	12,087,400)	13,218,000)	12,393,700)	12,917,600)	12,925,000)	13,255,600)	13,191,500)	13,932,800)	14,189,600)	14,222,600)	13,582,300)	13,895,200)	13,492,200)	13,338,800)	12,623,500)	12,257,300)	11,732,400)	11,699,200)	12,052,600)	11,054,500)	10,224,300)	10,185,400)	9,728,500)
Preferred stock, par value $0.001 per share	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)
Common stock, par value $0.0005 per share	100)	100)	100)	100)	100)	100)	100)	100)	100)	100)	100)	100)	100)	100)	100)	100)	100)	100)	100)	100)	100)	100)	100)
Additional paid-in capital	—)	—)	119,000)	68,200)	—)	—)	—)	—)	—)	—)	100)	—)	—)	—)	—)	—)	47,800)	—)	—)	97,800)	59,200)	19,300)	—)
Accumulated other comprehensive loss	(163,600)	(110,400)	(115,200)	(106,700)	(136,600)	(171,800)	(174,300)	(299,000)	(225,500)	(181,000)	(149,300)	(135,200)	(92,300)	(252,900)	(219,800)	(240,400)	(248,300)	(261,600)	(303,900)	(318,400)	(329,400)	(338,800)	(325,200)
Retained earnings	15,916,100)	14,959,900)	14,215,500)	13,911,700)	13,543,500)	13,900,700)	13,833,500)	13,976,300)	13,961,000)	14,466,700)	15,673,100)	16,455,400)	17,065,200)	16,182,800)	17,026,700)	16,257,000)	16,944,100)	15,499,500)	17,334,600)	15,810,400)	16,107,700)	14,881,700)	14,781,200)
Treasury stock, at cost	(2,977,100)	(2,977,100)	(2,977,100)	(2,977,100)	(2,977,100)	(2,977,100)	(2,977,100)	(2,977,100)	(2,977,100)	(2,977,100)	(2,977,100)	(2,977,100)	(2,977,100)	(2,977,100)	(2,977,100)	(2,977,100)	(2,977,100)	(2,977,100)	(2,977,100)	(2,977,100)	(2,977,100)	(2,977,100)	(2,977,100)
Total Biogen Inc. shareholders’ equity	12,775,500)	11,872,500)	11,242,300)	10,896,200)	10,429,900)	10,751,900)	10,682,200)	10,700,300)	10,758,500)	11,308,700)	12,546,900)	13,343,200)	13,995,900)	12,952,900)	13,829,900)	13,039,600)	13,766,600)	12,260,900)	14,053,700)	12,612,800)	12,860,500)	11,585,200)	11,479,000)
Noncontrolling interests	(8,700)	(9,100)	(21,600)	63,500)	451,800)	462,900)	(19,000)	(14,200)	(14,000)	(19,500)	(10,000)	(4,100)	(4,100)	(4,100)	(7,900)	(8,000)	(6,800)	(7,200)	(16,200)	(14,700)	(11,600)	(11,600)	(11,600)
Total equity	12,766,800)	11,863,400)	11,220,700)	10,959,700)	10,881,700)	11,214,800)	10,663,200)	10,686,100)	10,744,500)	11,289,200)	12,536,900)	13,339,100)	13,991,800)	12,948,800)	13,822,000)	13,031,600)	13,759,800)	12,253,700)	14,037,500)	12,598,100)	12,848,900)	11,573,600)	11,467,400)
Total liabilities and equity	24,854,200)	25,081,400)	23,614,400)	23,877,300)	23,806,700)	24,470,400)	23,854,700)	24,618,900)	24,934,100)	25,511,800)	26,119,200)	27,234,300)	27,484,000)	26,287,600)	26,445,500)	25,288,900)	25,492,200)	23,952,900)	26,090,100)	23,652,600)	23,073,200)	21,759,000)	21,195,900)

Current Portion of Notes Payable: The current portion of notes payable shows considerable fluctuation over the periods. Initially, high values around 560,000 US$ were followed by a sharp drop to near 3,200 US$ by the end of 2017. Thereafter, data are missing for several quarters, but in late 2019 it spikes to over 1,495,000 US$ before again dropping in 2022 to just under 1,000,000 US$.
Taxes Payable: Taxes payable reveal volatility with multiple peaks and troughs. After moderate amounts in 2017, a spike occurs in early 2018 reaching above 230,000 US$, then large oscillations follow, including a notable peak above 576,700 US$ in mid-2020, with a downward trend in late 2021 and 2022, ending at approximately 237,300 US$.
Accounts Payable: Accounts payable remain relatively stable but with some increases toward the later periods. The values generally fluctuate in the 300,000 to 400,000 US$ range, with significant rises in 2019 and 2022, notably peaking near 589,200 US$ in early 2022.
Liabilities Held for Sale: Data for liabilities held for sale are only available in the 2019 period, showing values in the range of approximately 88,600 to 97,200 US$. This suggests a possible one-time item or discontinued operation in that timeframe.
Accrued Expense and Other: Accrued expenses and other current liabilities show an upward trend during 2017 to 2018, followed by fluctuations hovering between 2,300,000 and 3,300,000 US$. There is a peak near the end of 2020 at over 3,280,000 US$, indicating increased short-term obligations, before stabilizing around lower values in subsequent quarters.
Current Liabilities: Current liabilities overall trend upward from approximately 2,992,500 US$ in early 2017 to a peak of about 5,018,000 US$ in mid-2022. The increase is gradual with intermittent fluctuations, suggesting expanded short-term financial obligations over the period.
Notes Payable, Excluding Current Portion: Long-term notes payable remain relatively stable, mostly near 5,900,000 US$ until the end of 2019, when a sharp increase to over 7,400,000 US$ occurs in mid-2020. Following this, a decline is observed in later periods with figures settling around 6,270,000 US$ in 2022.
Deferred Tax Liability: Deferred tax liabilities increase substantially from under 120,000 US$ in 2017 to a peak exceeding 2,820,000 US$ in late 2019. Subsequently, a downward trend emerges with levels diminishing to approximately 328,900 US$ by September 2022, indicating reductions in deferred tax obligations.
Long-Term Operating Lease Liabilities: This liability category emerges only in 2019 with values starting near 436,100 US$, followed by a gradual decline to about 274,200 US$ by mid-2022, consistent with the possible amortization or termination of lease obligations over time.
Other Long-Term Liabilities: Other long-term liabilities fluctuate between roughly 1,160,000 US$ and 1,650,000 US$ throughout the period, with no clear directional trend, reflecting relative stability in this liability component.
Long-Term Liabilities: Long-term liabilities overall increase from about 6,736,000 US$ in early 2017 to a peak around 10,775,000 US$ in mid-2020, then gradually decrease to just above 8,160,000 US$ by late 2022. This pattern suggests increased borrowing or obligations during 2018-2020 followed by deleveraging or amortization subsequent to that period.
Total Liabilities: Total liabilities follow a similar trend, increasing from approximately 9,728,500 US$ in early 2017 to nearly 13,895,200 US$ in late 2019, peaking then oscillating around 12,000,000 to 13,200,000 US$ in 2022. This indicates overall growth in liabilities with some moderation later in the time frame.
Common Stock, Par Value: The common stock par value remains constant at 100,000 US$ throughout the entire period, indicating no change in the shares' nominal value.
Additional Paid-in Capital: Additional paid-in capital shows inconsistency with missing data in many periods but contains notable spikes in mid-2017 and 2021, reaching values as high as 119,000 US$. The variability suggests occasional equity issuances or adjustments.
Accumulated Other Comprehensive Loss: The accumulated other comprehensive loss generally declines over time from about -325,200 US$ in early 2017, becoming less negative near -106,700 US$ in late 2021, before fluctuating again. This trajectory indicates a partial recovery in comprehensive income components offsetting accumulated losses.
Retained Earnings: Retained earnings display significant volatility, initially increasing to a peak above 17,300,000 US$ in early 2018, then declining significantly to roughly 13,960,000 US$ at the end of 2020. A recovery occurs in 2022, with retained earnings rising steadily above 15,900,000 US$ by the latest period, reflecting fluctuating profitability and dividend policies.
Treasury Stock, at Cost: Treasury stock remains constant at approximately -2,977,100 US$ across all periods, suggesting no new share buybacks or retirements during the timeframe analyzed.
Total Shareholders’ Equity: Total shareholders’ equity increases from about 11,479,000 US$ in early 2017 to a peak near 14,053,700 US$ in early 2018, followed by a decline reaching a low near 10,758,500 US$ in late 2020. The equity then gradually recovers, concluding around 12,775,500 US$ in late 2022, depicting overall equity fluctuation consistent with retained earnings trends and other equitized components.
Noncontrolling Interests: Noncontrolling interests mostly remain negative or near zero throughout the period, except for anomalous spikes in mid-2021 where they reach a positive 462,900 US$, followed by wide variations. This irregularity may be due to reclassification, acquisition, or divestiture effects.
Total Equity: Total equity mirrors the trends in shareholders' equity, showing increases from approximately 11,467,400 US$ in early 2017 to a peak around 14,037,500 US$ in early 2018, then declining to just above 10,661,000 US$ at the end of 2020. Recovery is observed into 2022, ending near 12,766,800 US$, reflecting similar drivers as previously noted.
Total Liabilities and Equity: The total of liabilities and equity grows steadily from roughly 21,195,900 US$ in early 2017 to a maximum of about 27,484,000 US$ in late 2019. Post-2019, slight decline and fluctuations occur, with figures ending near 24,854,200 US$ in the latest period, indicating consolidation of financial structure after peak expansion years.

Download chart

Biogen Inc. (NASDAQ:BIIB)

Balance Sheet: Liabilities and Stockholders’ Equity Quarterly Data

Balance Sheet: Liabilities and Stockholders’ Equity
Quarterly Data